OA06.01 Clinical Utility of Circulating Tumor DNA (ctDNA) Analysis by Digital next Generation Sequencing of over 5,000 Advanced NSCLC Patients
Philipp Mack(University of California Davis Medical Center), David R. Gandara(University of California, Davis), Darya Chudova(Guardant (United States)), Richard B. Lanman(C.T. de Wit Graduate School for Production Ecology and Resource Conservation), Justin I. Odegaard(Guardant (United States)), Oliver A. Zill(Guardant (United States)), AmirAli Talasaz(Guardant (United States)), Jonathan W. Riess(University of California Davis Medical Center), Rebecca J. Nagy(Guardant (United States)), Christine Lee, Helmy Eltoukhy(Guardant (United States)), Kimberly C. Banks(Guardant (United States)), Stefanie Mortimer(Guardant (United States))
Cited by 6
Related Papers
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2008|3.2k
Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2022|1.4k
Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab
|Nature Medicine|2018|1.2k
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%
|Journal of Clinical Oncology|2021|1.1k